ABSTRACT
Racial and ethnic disparities in COVID-19 outcomes reflect the unequal burden experienced by vulnerable communities in the United States (US). Proposed explanations include socioeconomic factors that influence how people live, work, and play, and pre-existing comorbidities. It is important to assess the extent to which observed US COVID-19 racial and ethnic disparities can be explained by these factors. We study 9.8 million confirmed cases and 234,000 confirmed deaths from 2,990 US counties (3,142 total) that make up 99.8% of the total US population (327.6 out of 328.2 million people) through 11/8/20. We found national COVID-19 racial health disparities in US are partially explained by various social determinants of health and pre-existing comorbidities that have been previously proposed. However, significant unexplained racial and ethnic health disparities still persist at the US county level after adjusting for these variables. There is a pressing need to develop strategies to address not only the social determinants but also other factors, such as testing access, personal protection equipment access and exposures, as well as tailored intervention and resource allocation for vulnerable groups, in order to combat COVID-19 and reduce racial health disparities.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Resource support was provided by the Cannon cluster supported by the FAS Division of Science, Research Computing Group at Harvard University. This work was funded by NIH grant T32-CA933739 (DL), HD092580 (JTC and BAC), and R35-CA203654-04 (XL).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
We registered to join the COVID-19 Data Consortium and access SafeGraph COVID-19 response data on 5/12/2020 by signing the SafeGraph Coronavirus Non-Commercial Data License Agreement (license version dated 4/17/2020). We did not receive a unique registration ID or approval code associated with our registration. The SafeGraph Coronavirus Non-Commercial Data License Agreement stipulates that SafeGraph data cannot be distributed for purposes other than those SafeGraph must be credited as the originator of SafeGraph data in publications or other content that use SafeGraph data. SafeGraph is a private company. SafeGraph COVID-19 data is derived from anonymous cellular location data, which are not associated with individual names or email addesses. The data are aggregated across devices within geographic units. The registration process is free-of-charge for all. All other data are publicly available online without registration.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All materials and code for analysis are available on https://github.com/lin-lab/COVID-Health-Disparities.
